Barriers to intravenous thrombolysis in acute ischemic stroke: a retrospective case report series from Honduras.
- 1Faculty of Medical Sciences, National Autonomous University of Honduras (UNAH), Tegucigalpa, Honduras.
Abstract
Background and purpose
Intravenous (IV) thrombolysis for acute ischemic stroke (AIS) is time-dependent and frequently underused in resource-limited settings. We aimed to characterize patients with AIS who did not receive IV thrombolysis at a national referral center in Honduras and to document the barriers to treatment.Methods
We conducted a retrospective, single-center, consecutive case report series of all eligible patients with AIS who were not thrombolyzed at Hospital Escuela Universitario between 1 October and 30 November 2025. We gathered demographics, socioeconomic status, admission severity, process-of-care intervals, contraindications, neuroimaging and thrombolytic availability, complications, and discharge outcomes. Contraindications were classified as absolute or relative according to the 2019 American Heart Association and American Stroke Association (AHA/ASA) guidelines. A thrombolysis eligibility cascade was the principal analysis. The study was approved by the institutional review board.Results
A total of 23 patients were included (median age 70 years; 14 [60.9%] male). Extreme poverty (≥2 unsatisfied basic needs [UBN]) was present in 14 patients (60.9%). All 23 AIS presentations screened during the period were included, and no patient received thrombolysis (institutional thrombolysis rate 0%). The median onset-to-door time was 10.0 h (IQR 7.0-15.0), and only 1 of 22 patients with a recorded time (4.5%) arrived within 4.5 h. Late or unknown onset was the most frequent absolute contraindication (21 [91.3%]); neuroimaging was available in 22 (95.7%) patients, but the thrombolytic agent was unavailable in every patient (availability 0%). In the eligibility cascade, the single patient within the window had no absolute contraindication and could not be treated because no thrombolytic agent was available. The in-hospital mortality rate was 2 (8.7%), and a good functional outcome (modified Rankin Scale [mRS] score 0-2) occurred in 5 of 20 patients with an assessable score.Conclusion
Non-administration of thrombolysis reflected late presentation and, above all, the complete unavailability of the thrombolytic agent, whereas imaging and organizational capacity were largely in place. Drug supply was the proximate, modifiable obstacle to reperfusion in this setting.
Related
- The C-reactive protein–albumin–lymphocyte (CALLY) index in early hospital presentation and intravenous thrombolysis in acute ischemic stroke : A retrospective study
- A cumulative biochemical profile of low uric acid and high total bilirubin is associated with hemorrhagic transformation after intravenous thrombolysis in acute ischemic stroke: a retrospective cohort study
- Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke
- Success rate and determinants of intravenous thrombolysis in acute ischemic stroke from the Malaysia National Stroke Registry
- Machine learning-based models to predict 90-day non-excellent functional outcomes among patients with mild acute ischemic stroke after intravenous thrombolysis
BibTeX
@article{santos2026barriers,
title = {{Barriers to intravenous thrombolysis in acute ischemic stroke: a retrospective case report series from Honduras.}},
author = {Jesús Antonio Rodríguez Santos and Iván Pineda and Eliezer Cardona and Carlos Maradiaga and Juan Galeano and Laura Giacaman and Selvin Z Reyes-Garcia},
journal = {Frontiers in stroke},
year = {2026},
month = oct,
doi = {10.3389/fstro.2026.1946997},
url = {https://europepmc.org/article/MED/42922779},
note = {CC BY},
}
RIS
TY - JOUR
TI - Barriers to intravenous thrombolysis in acute ischemic stroke: a retrospective case report series from Honduras.
AU - Jesús Antonio Rodríguez Santos
AU - Iván Pineda
AU - Eliezer Cardona
AU - Carlos Maradiaga
AU - Juan Galeano
AU - Laura Giacaman
AU - Selvin Z Reyes-Garcia
PY - 2026
DA - 2026/10/08
JO - Frontiers in stroke
DO - 10.3389/fstro.2026.1946997
UR - https://europepmc.org/article/MED/42922779
AB - Background and purpose Intravenous (IV) thrombolysis for acute ischemic stroke (AIS) is time-dependent and frequently underused in resource-limited settings. We aimed to characterize patients with AIS who did not receive IV thrombolysis at a national referral center in Honduras and to document the barriers to treatment.Methods We conducted a retrospective, single-center, consecutive case report series of all eligible patients with AIS who were not thrombolyzed at Hospital Escuela Universitario between 1 October and 30 November 2025. We gathered demographics, socioeconomic status, admission severity, process-of-care intervals, contraindications, neuroimaging and thrombolytic availability, complications, and discharge outcomes. Contraindications were classified as absolute or relative according to the 2019 American Heart Association and American Stroke Association (AHA/ASA) guidelines. A thrombolysis eligibility cascade was the principal analysis. The study was approved by the institutional review board.Results A total of 23 patients were included (median age 70 years; 14 [60.9%] male). Extreme poverty (≥2 unsatisfied basic needs [UBN]) was present in 14 patients (60.9%). All 23 AIS presentations screened during the period were included, and no patient received thrombolysis (institutional thrombolysis rate 0%). The median onset-to-door time was 10.0 h (IQR 7.0-15.0), and only 1 of 22 patients with a recorded time (4.5%) arrived within 4.5 h. Late or unknown onset was the most frequent absolute contraindication (21 [91.3%]); neuroimaging was available in 22 (95.7%) patients, but the thrombolytic agent was unavailable in every patient (availability 0%). In the eligibility cascade, the single patient within the window had no absolute contraindication and could not be treated because no thrombolytic agent was available. The in-hospital mortality rate was 2 (8.7%), and a good functional outcome (modified Rankin Scale [mRS] score 0-2) occurred in 5 of 20 patients with an assessable score.Conclusion Non-administration of thrombolysis reflected late presentation and, above all, the complete unavailability of the thrombolytic agent, whereas imaging and organizational capacity were largely in place. Drug supply was the proximate, modifiable obstacle to reperfusion in this setting.
SN - 2813-3056
ER -